INDIA'S IPCA ACQUIRES RIGHTS TO WYETH CARDIOVASCULAR TREATMENT

Company sources indicate that India-based drug manufacturer Ipca Laboratories is to acquire US-based drug major Wyeth's Isordil (isosorbide dinitrate) cardiovascular treatment. The decision to sell the brand, which is used in the lucrative and fast-growing cardiac treatments segment, was attributed to Wyeth's limited global presence.

Ipca is now widely expected to manufacture the drug for export, a business area which currently accounts for over half the company's annual income. In addition to its formulations and distribution businesses, Ipca also produces its own range of active pharmaceutical ingredients, including the antihypertensive Atenolol, antimalarial product Chloroquine Phosphate, and the diuretic Furosemide.